On Monday, Prime Medicine Inc (NASDAQ: PRME) was 10.65% up from the session before settling in for the closing price of $4.13. A 52-week range for PRME has been $1.11 – $5.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -124.13% over the past five years. When this article was written, the company’s average yearly earnings per share was at 23.78%. With a float of $52.90 million, this company’s outstanding shares have now reached $131.16 million.
Let’s look at the performance matrix of the company that is accounted for 214 employees. In terms of profitability, gross margin is 95.87%, operating margin of -496.2%, and the pretax margin is -485.69%.
Prime Medicine Inc (PRME) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Prime Medicine Inc stocks. The insider ownership of Prime Medicine Inc is 60.67%, while institutional ownership is 28.35%. The most recent insider transaction that took place on Jun 30 ’25, was worth 52,830. In this transaction 10% Owner of this company bought 21,000 shares at a rate of $2.52, taking the stock ownership to the 20,240,945 shares. Before that another transaction happened on Jun 23 ’25, when Company’s 10% Owner bought 21,000 for $2.16, making the entire transaction worth $45,402. This insider now owns 20,219,945 shares in total.
Prime Medicine Inc (PRME) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 23.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.47% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
You can see what Prime Medicine Inc (PRME) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 159.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Prime Medicine Inc (NASDAQ: PRME) saw its 5-day average volume 6.32 million, a positive change from its year-to-date volume of 2.28 million. As of the previous 9 days, the stock’s Stochastic %D was 38.18%.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 85.22%, which indicates a significant increase from 79.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.57 in the past 14 days, which was higher than the 0.25 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.25, while its 200-day Moving Average is $2.65.
